Antisense Targeting of cFLIP Sensitizes Activated T Cells to Undergo Apoptosis and Desensitizes Responses to Contact Dermatitis  by Mourich, Dan V. et al.
Antisense Targeting of cFLIP Sensitizes Activated
T Cells to Undergo Apoptosis and Desensitizes
Responses to Contact Dermatitis
Dan V. Mourich1,2, Jessica L. Jendrzejewski3, Nikki B. Marshall2, David J. Hinrichs4, Patrick L. Iversen1
and Rhonda M. Brand3,5
Contact dermatitis is the result of inflammatory responses mediated by hapten-specific activated CD8þ and
CD4þ T cells. Activation-induced cell death (AICD) is a naturally occurring process regulating the resolution of
T-cell responses through decreased expression of the antiapoptotic molecule cellular FLICE inhibitory protein
(cFLIP). We show that targeting cFLIP expression in vitro and in vivo, with morpholino antisense applied
systemically or topically in conjunction with antigen, sensitizes T cells to undergo ‘‘early’’ AICD resulting in
tolerance. Analysis of antisense-treated CD8þ OT-1 splenocytes after co-culture with SIINFEKL-pulsed DCs
showed apoptosis occurring in a dose-dependent manner with respect to cFLIP peptide-conjugated
phosphorodiamidate morpholino oligomer (PPMO) concentration. A transplant acceptance model using male
DO.11 donor cells and female BALB/c recipient mice showed that cFLIP antisense treatment could promote
antigen tolerance. Hypersensitivity responses induced in mice by the epicutaneous application of the haptens
FITC and oxazolone confirmed that topically applied cFLIP antisense could reduce inflammation. Treatment of
the skin produced significant reduction in dermatitis and localized infiltration of lymphocytes. Moreover, the
treatment was target- and antigen-specific, dose-dependent, and capable of inducing long-lived tolerance.
These data suggest that the targeted expression of immune-regulating molecules is possible through the
application of antisense to the skin.
Journal of Investigative Dermatology (2009) 129, 1945–1953; doi:10.1038/jid.2009.16; published online 19 February 2009
INTRODUCTION
Contact dermatitis results in 5.6 million doctor visits each year in
the United States and accounts for 15–20% of all occupational
diseases. Including lost workdays and productivity losses, the
estimated total annual costs associated with occupational skin
diseases approach $1 billion annually in the United States
(Centers for Disease Control) and up to $3 billion annually in
Germany (Merk et al., 2006). Overall 80% of contact dermatitis
is due to irritants, whereas the remaining 20% are classified as
allergic. The first-line therapeutic agents for contact dermatitis
are topical corticosteroids. Long-term use can result in numerous
local and systemic side effects. Systemic steroids are also
effective, but side effects greatly limit their use. Topical
immunosuppressive drugs such as tacrolimus that can success-
fully treat atopic dermatitis are also being examined for their
potential to treat contact dermatitis. There is some concern,
however, about potential increases in cancer risks associated
with their use (Seyfarth et al., 2008). The advent of effective new
agents for contact dermatitis treatment would be a valuable
contribution to the field of dermatology.
Contact dermatitis and many hypersensitivity reactions of the
skin are a result of haptens as low-molecular-weight molecules
or metal ions reacting with cellular proteins that are processed
into peptides and presented on the surface of Langerhans cells,
the principal antigen-presenting cells of the epidermis (Saint-
Mezard et al., 2003). After maturation, Langerhans cells migrate
to regional lymph nodes and present hapten-modified peptides
in the context of major histocompatibility class I and II molecules
to hapten-specific CD8þ and CD4þ T cells, respectively
(Saint-Mezard et al., 2004a). Activation of antigen-specific T
cells constitutes the sensitization phase of contact sensitivity
responses, and subsequent exposure to hapten, the challenge
phase causes effector memory T cells to migrate into the skin.
Here, antigen recognition induces T cells to express various
mediators of inflammation and cytotoxicity, ultimately causing
dermatitis and tissue damage (Saint-Mezard et al., 2004b).
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Antigen activation occurs through the TCR and through
interaction with co-stimulatory molecules (for example,
CD28/CD80) expressed on responding T cells and antigen-
presenting cells. This leads to significant T-cell proliferation
followed by an equally significant contraction phase. Levels
of Fas and FasL change with the activation state of various
leukocytes, and modulation of the extrinsic pathway of
apoptosis is critical to controlling the expansion and
contraction phases of T cells through protection from or
sensitization to activation-induced cell death (Thome and
Tschopp, 2001). A major step in the extrinsic pathway
leading to apoptosis is the conversion of procaspase-8 into its
active form, caspase-8 (FADD-like IL-1 b-converting enzyme
or FLICE). The first inhibitor of caspase-8 was discovered as a
virally encoded protein that functioned by inhibiting its
conversion (Thome et al., 1997). Many viruses inhibit host
cell apoptosis by producing similar molecules (for example,
human herpes virus 8; Sun et al., 2003), and these
viral-derived inhibitors were named vFLIPs (viral-derived
FLICE-inhibitory proteins).
Soon it became apparent that cells also have the capacity
to regulate the extrinsic pathway (Irmler et al., 1997). Cellular
apoptosis inhibitors acting in a similar fashion to vFLIPs were
named cellular FLICE inhibitory proteins (cFLIPs). Although
multiple splice variants exist, only two cFLIP proteins are
identified, cFLIPS and cFLIPL. Procaspase-8 and all FLIPs
contain tandem death effector domains, although cFLIPL is
more similar to procaspase-8 because it has an inactive
caspase-like domain owing to the deletion of amino-acid
residues within the catalytic center (Krueger et al., 2001a).
Although some details of cFLIP inhibition of the extrinsic
pathway remain to be established, it is evident that cFLIPS
completely prevents caspase-8 processing, whereas cFLIPL
induces a conformation of procaspase-8 that allows partial
but not complete proteolytic processing of procaspase-8 to its
active state (Krueger et al., 2001b). Additional anti-apoptotic
activities are attributed to cFLIP besides interference with
caspase-8 activation (Chang et al., 2002; Kim et al., 2003).
Upregulation of cFLIP expression as a consequence of TCR
engagement causes T cells to resist Fas-mediated apoptosis
(Kirchhoff et al., 2000) and resistance correlates with
increased de novo synthesis of cFLIPs (Schmitz et al.,
2004). In addition, cFLIPL is essential for T-cell proliferation
through an NF-kB-independent pathway (Zhang et al., 2008).
Increased expression of cFLIPL after cross-linking of the B-cell
receptor and monocyte to macrophage differentiation is also
associated with the inhibition of Fas-mediated apoptosis
(Perlman et al., 1999; Wang et al., 2000). Although signaling
pathways associated with apoptosis and immunoregulation
are complex and not completely understood, cFLIP is one
antiapoptotic molecule crucial to leukocyte survival after
activation differentiation and death receptor ligation
(Thorburn, 2004). Thus, inhibiting cFLIP expression during a
T-cell-mediated immune response would place responding
cells at risk for apoptosis and result in clonal deletion without
involvement of non-responding T-cell populations.
Dermal penetration is a highly desirable delivery strategy
for antisense compounds and is a logical manner to prevent
or treat contact dermatitis through local modulation of cFLIP
expression. Although traditional wisdom suggests that anti-
sense oligonucleotides are too large to penetrate the stratum
corneum, the possibility of using these compounds to treat
dermal disorders has been addressed by multiple laboratories
(Brand, 2001; Isomura et al., 2006; Lazou et al., 2007).
Advances in antisense chemistry, including modified back-
bones and sugar moieties that increase potency combined
with better delivery methods, improve the feasibility of this
technique. Drug potency can be enhanced using modified
chemistries, thereby increasing the likelihood of delivering
therapeutic levels into the skin. Phosphorodiamidate
morpholino oligomers (PMO) have a non-ionic phosphoro-
diamidate backbone combined with a morpholine ring that
replaces both the deoxyribose sugar and one of the non-
bridging oxygen atoms with dimethylamine. These modifica-
tions improve oligomer hybrid duplex stability, have minimal
non-antisense activity, good aqueous solubility, low produc-
tion costs (Summerton and Weller, 1997), are resistant to
nucleases (Hudziak et al., 1996), and have high specificity
and better efficacy than other types of antisense (Stein et al.,
1997). We have shown earlier that arginine-containing
peptide-conjugated PMO (PPMO) effectively alter mRNA
splicing and expression of targeted proteins in murine
leukocytes in a dose- and time-dependent manner (Marshall
et al., 2007). In this study, we show that PPMO antisense
blockade of cFLIP expression can induce apoptosis in
activated T cells and, furthermore, can significantly inhibit
dermatitis when applied to the skin during the challenge
phase of a hypersensitivity model.
RESULTS
Inhibition of cFLIP protein expression in T cells treated with
PPMO
We first sought to determine whether an antisense morpho-
lino agent targeting the AUG translational initiation sequence
affects protein expression. Figure 1 shows the expression
levels of cFLIP long and cFLIP short isomers after treatment of
anti-CD3-activated T cells in culture. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and actin blots were
run before the cFLIP blots to establish equivalent loading for
the PPMO targeting comparison. Expression of both forms of
cFLIP was diminished by treating cells with cFLIP PPMO,
which is not surprising as these isomers share the same
translational initiation sequence within the mature mRNA.
Treatment of cells with control PPMO did not affect protein
levels confirming specificity of the antisense effect. Interest-
ingly, we did observe an additional higher-molecular-weight
band in the GAPDH blot when cells treated with cFLIP PPMO
were compared with control or untreated cells. Typically,
GAPDH is used as a ‘‘housekeeping’’ gene for monitoring
steady-state transcription or translation for assay conditions.
However, in addition to glycolysis, a role in apoptosis has
been attributed to the differential expression of GAPDH.
Furthermore, it has been shown in neurons that cellular
stresses, including those leading to apoptosis, can induce
insoluble aggregation of GAPDH and appear as a higher-
molecular-weight band in blot analysis (Nakajima et al.,
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2007). Although such results have yet to be described for
T cells, this likely accounts for the higher-molecular-weight
band reactive to anti-GAPDH observed for the sample
receiving cFLIP PPMO.
Antigen-specific induction of apoptosis in cFLIP-treated T cells
Evidence of antigen-specific activation-induced cell death in
ovalbumin (OVA)-specific CD8þ T cells was observed when
splenocytes were treated with cFLIP PPMO compared with
those treated with control PPMO or stimulation through
presentation of an irrelevant peptide. Splenocytes from
OVA-specific TCR transgenic (OT-1) mice recognizing the
OVA-derived H-2K(b)/SIINFEKL peptide complex were trea-
ted with cFLIP PPMO (1–12mM), control PPMO (12mM), or
media control for 16 hours. The pretreated splenocytes were
then co-cultured with DCs previously pulsed with SIINFEKL
or an irrelevant peptide. Apoptosis was analyzed by
examining Annexin V staining in the population of CD8þ
cells after gating on the 7-ADD-negative population. OT-1-
derived CD8þ cells receiving antigen-specific activation
after treatment with cFLIP PPMO showed a dose-dependent
increase in Annexin V staining (Figure 2) compared with
those treated with control PPMO or those treated with cFLIP
PPMO and exposed to an irrelevant antigen. A calculated
EC50 was estimated to be 6.6 nM (Figure 2 inset graph).
Similar experiments were conducted using splenocytes
derived from DO.11 mice and co-cultured with autologous
DCs pulsed with OVA. These results also showed that cFLIP
treatment induced signs of apoptosis in KJ26þ T cells, as it
decreased membrane integrity and increased caspase-3
activity in a manner dependent on cFLIP treatment and
exposure-specific antigen (data not shown).
Systemic delivery of cFLIP PPMO promotes transplant survival
On the basis of earlier in vitro results, we designed an
experiment to test the in vivo efficacy of this approach. For
these studies, we transferred T cells from male DO.11
transgenic mice into normal BALB/c recipients. The male
CD4þ T cells are identified by using the KJ26 antibody that
binds to the TCR receptor of these transgenic T cells. Thus, after
the transfer of DO.11 T cells into BALB/c recipients, transferred
cells are enumerated by FACS analysis. It has been established
by others that the male H-Y antigen is recognized as an
alloantigen by female recipient T cells resulting in the rejection
of the male cells (Fierz et al., 1982; Beaulieu et al., 1998). The
recognition of this minor histocompatibility difference is T-cell-
dependent and involves both CD4þ and CD8þ T-cell
populations (VanderVegt and Johnson, 1993). To test this, we
injected male DO.11 T cells into female BALB/c recipients and
after 14 days were stained for the presence of KJ26þ T cells in
splenocytes of recipients. At that time, female recipients show a
95% reduction in the number of KJ26þ cells compared with
the number of KJ26þ cells found in a group of BALB/c male
recipients (data not shown). This indicated that female mice
recognized the H-Y antigen and developed an immune
response capable of rejecting DO.11 male cells.
To determine the in vivo influence of cFLIP PPMO, we
conducted an experiment in which female BALB/c mice
(N¼7 per treatment group) were injected with KJ26þ T cells
obtained from male DO.11 mice. Recipient mice were then
administered either cFLIP PPMO or cFLIP PMO (not
conjugated to the delivery peptide), or a scramble sequence
control PPMO or no treatment. We also injected female
BALB/c mice with female DO.11 T cells to determine the
baseline of homeostatic maintenance of these cells when
transferred into gender-matched recipients. Daily treatments
were administered at a dose of B10mgkg1. The animals
were treated until the day of euthanasia (day 14 after cell
infusion), at which time the numbers of KJ26þ cells were
determined in spleens of mice from all groups. As is evident
in Figure 3, treatment with cFLIP PPMO prevented rejection
of the KJ26þ cells in female recipients. In contrast, animals
receiving treatment with cFLIP PMO (the non-conjugated
form) did not retain the same levels of KJ26þ cells,
confirming the necessity of the delivery peptide to affect
T-cell activity. Groups of mice that received either no
injections of antisense or the group that received PPMO
scramble had a significant reduction in KJ26þ cells. As
expected, female recipients retained the female KJ26þ cells.
There is no significant difference in KJ26þ cell numbers
detected between female recipients and cFLIP PPMO-treated
female recipients of male KJ26þ cells.
Following the assessment of transplant success, the
functional activity of transplanted KJ26þ cells in the cFLIP-
PPMO treated mice was examined by intracellular cytokine
staining after culturing the recipient splenocytes with OVA.
This confirmed that the retained KJ26þ cells were not merely
dead cells. Figure 3b shows an example of the functional
activity of these cells recovered from cFLIP treatment group
responding to OVA by measurement of cytokine production.
Topical application of cFLIP PPMO promotes tolerance to
contact allergy
The contact allergy response in BALB/c mice was determined
after FITC sensitization by measuring differences in ear
Untreated cFLIP Control
cFLIP L
cFLIP S
GAPDH
Actin
Figure 1. Inhibition of cFLIP protein expression shown in T cells after
treatment with PPMO targeting AUG start site. Purified BALB/c splenic
T cells were cultured 24hours with plate-bound anti-CD3 (5mgml1) and
treated with or without PPMO (5 mM) targeting the AUG start site of murine
cFLIP or scrambled control sequence. Western blot analysis was performed to
determine protein expression levels and equivalent sample loading by prior
examination of GAPDH and actin levels.
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thickness between the treated and untreated ear. Effective-
ness was determined by comparing thickness changes in ears
from sensitized mice without any topical treatment (Figure
4a). The cFLIP PPMO applied in vehicle (95% PG/5% LA)
reduced the swelling by 73% (Po0.001), whereas the same
PPMO given in water led to a nonsignificant 17% decrease,
similar to vehicle alone.
Figure 4b shows that topical cFLIP PPMO reduces
FITC-induced contact allergy in a dose-dependent
manner. Applying 3mg/ear caused a 21% decrease in ear
thickness (P40.05). Increasing the dose to 30, 300, and
3,000mg/ear lessened ear thickness by 57, 70, and 96%,
respectively (Po0.001). Using a scrambled PPMO sequence
at 300mg/ear caused only a nonsignificant 12% reduc-
tion similar to the 17% decrease seen after treatment with
vehicle alone.
A second study was performed to ensure that cFLIP PPMO
could reduce contact allergy with antigens other than FITC.
The sensitizing agent, oxazolone, was therefore used as a
second model antigen. As shown in Figure 4c, oxazolone
alone caused a 15.7102mm increase in ear thickness,
whereas treatment with 300mg/ear cFLIP PPMO decreased
this response by 70% (Po0.01).
The impact of PPMO treatment on leukocyte infiltration
was examined through hematoxylin and eosin staining
(Figure 5a and b). The number of leukocytes in a 100mm2
area was quantitated in 10 sections and averaged. FITC
treatment significantly increased the number of leukocytes
(Po0.05) present in the skin by 37%, whereas adding cFLIP
PPMO before treatment reduced the FITC-triggered increase
to only 5% above control. Immunohistochemistry was
performed to examine the distribution of cFLIP-positive cells
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Figure 2. Dose-dependent effect of cFLIP PPMO treatment on antigen-specific activation-induced cell death (AICD). The extent of apoptosis was examined by
flow cytometry gating on lymphocytes (R1) that were CD8þ , 7-AAD-negative (R2), and staining Annexin-V-positive (R3). Histogram traces: cFLIP PPMO of 12,
6, and 3 and 1 mM are indicated as thick black, thin black, and dotted and dashed lines, respectively. Control PPMO (12 mM) is indicated as thick gray line.
Splenocytes treated with 12mM cFLIP PPMO and stimulated with DCs pulsed with irrelevant peptide are indicated as thin gray line. Inset graph shows a log
dose-dependent effect of the number of cells undergoing apoptosis increases with the concentration of cFLIP PPMO. Dose is represented on the abscissa as a log
micromolar (mM) concentration and the number of apoptotic cells observed is represented on the ordinate. The goodness of fit is measured as R2¼0.9952 and
EC50. These data are representative of two separate experiments.
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Figure 3. Treatment of transplant recipients with cFLIP PPMO promotes the survival of transplanted male cells that retain functional activity. Female BALB/c
mice (N¼4) were treated with cFLIP PPMO, scramble PPMO, or left untreated 3 days before and 7 days after transplantation of male DO.11 splenocytes.
Animals were killed 14 days post transplantation and their spleens examined for the presence of KJ26þ cells by FACS analysis. (a) The average total number of
surviving KJ26þ cells for each treatment group was calculated by flow cytometry analysis and cell counts for individual animals. (b) Functional activity of
KJ26þ cells in cFLIP PPMO-treated mice was examined by intracellular cytokine staining after culturing the recipient splenocytes with OVA. An example of one
mouse from the cFLIP PPMO treatment group responding to OVA by production of IL-4 and IFN-g is shown. Cytokine production in cultures not pulsed with
OVA produced was o0.01 % of the KJ26þ cells. These data are representative of two separate experiments.
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Figure 5. Histological analysis. (a) Hematoxylin and eosin (H&E)-stained ear sections after contact allergy treatment showing differences in leukocyte
infiltration after FITC induction and treatment with cFLIP PPMO (Bar¼20 mm). (b) Number of leukocytes in 100mm2 area of ear averaged over 10 different
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within the skin for each treatment group. Ear swelling was
correlated with the infiltration of cFLIP-positive cells and
topical application of PPMO with FITC decreased cFLIP-
positive cells (Figure 5c).
Two weeks later, the opposite ear was treated with
FITC and the ability of the original cFLIP PPMO applications
to generate a T-cell memory response was examined. The
second FITC application generated a smaller change in ear
thickness compared with the original treatment (0.043 vs
0.08mm). Animals given PPMO before the initial ear
application were less sensitive to the second treatment. Mice
receiving 3mg/ear had a 23% less ear thickening than vehicle
alone, whereas those getting 30 300, and 3,000mg/ear had
reduced ear thickness by 47% (Po0.05), 35% (P40.05), and
54%, respectively (Po0.01); Figure 6a). Figure 6b compares
the challenge dose response and memory results. The initial
challenge data showed a greater dose response than did the
long-term memory study.
The ability of cFLIP PPMO to affect memory function after
sensitization with oxazolone is shown in Figure 6c.
Re-treating the skin 2 weeks later with oxazolone triggered
a 10.8102mm thickening of the ear. The initial PMO
treatment was able to reverse 49% of this response (Po0.01).
DISCUSSION
These data show that topically applied PPMO antisense
targeting cFLIP can reduce skin inflammation in sensitized
animals. PPMO was dissolved in 95% propylene glycol/5%
linoleic acid, because in earlier studies this formulation was
proven effective at allowing biologically relevant levels of
compound to absorb into the skin. Antisense PMO targeted to
cytochrome P450 (CYP) 3A2 was topically applied to adult
male rats, and CYP3A enzyme activity in underlying skin and
liver was evaluated 24 hours after application. Topical
delivery of 0.03mg PMO reduced skin enzyme levels by
half (Arora et al., 2002). Although this formulation would not
be appropriate as a commercial product as propylene glycol
can be irritating to many individuals (Lashmar et al., 1989), it
is an effective starting point to show potential success. The
importance of vehicle is evident in this study, as the cFLIP
PPMO dissolved in water was not effective at preventing
FITC-induced inflammation.
Several papers have shown the ability of oligonucleotides
with different chemistries to enter and cross skin in vitro
(Nolen et al., 1994; Oldenburg et al., 1995; Brand and
Iversen, 1996; Regnier et al., 1999) and in vivo (Brand, 2001;
Isomura et al., 2006; Lazou et al., 2007). Others have had less
success in delivering antisense oligonucleotides into the skin,
and this may be a function of the formulations that were used
(Wraight and White, 2001). For example, we examined the
influence of vehicle on the transdermal delivery of several
PMO with different sizes, lengths, base compositions,
sequences, and lipophilicities, and showed that the combina-
tion of sequence and formulation could modulate penetration
through the skin (Pannier et al., 2004). We have also shown
that some sequences can be more effective as topical agents
because they interact with keratinocytes better than others
(Brand et al., 1997). Dokka et al. (2005) found that applying a
20-O-methoxyethyl-modified oligonucleotide targeting
ICAM-1 in a cream caused follicular accumulation followed
by dermal accumulation, whereas using a saline formulation
caused the oligonucleotide to remain within the hair follicle
(). Furthermore, a comparison between topical and intrave-
nous delivery of a phosphorothioate oligonucleotide targeted
to ICAM-1 showed three orders of magnitude more com-
pound in the epidermis and two orders of magnitude more in
the dermis for topical application, with accumulation in
epidermal keratinocyte nuclei and in dermal fibroblasts.
Antisense metabolism was also lower with topical applica-
tion than intravenous (Mehta et al., 2000).
The feasibility of using topical antisense to treat dermal
disorders has been shown for a number of targets. A
phosphorothioate antisense oligonucleotide to transforming
growth factor-b1 decreased scarring of incision wounds when
applied topically to mice (Cordeiro et al., 2003). Several
investigators have examined topically applied oligonucleo-
tides to treat dermatitis. A phosphorothioate NF-kB decoy
oligonucleotide in a gel formulation effectively penetrates
into the pig skin. It was also able to obtain ‘‘steroid-like’’
efficacy in a chronic skin inflammation model by restoring
barrier function in mice (Dajee et al., 2006). Similar results
were seen with an antisense oligonucleotide to IL-10
delivered by iontophoresis (Sakamoto et al., 2004) A
phosphorothioate to IL-8 applied in an ointment was able
to inhibit cytokine levels in mice and reduced ear thickness in
sensitized mice (Dorn et al., 2007). Additionally, a chimeric
oligonucleotide was able to restore melanin synthesis in
albino BALB/c mice when given either topically or intrader-
mally. The gene correction remained for 3 months after
oligonucleotide application (Alexeev et al., 2000).
One possible method of targeting T cells specifically is the
inhibition of cFLIP during the stage of antigen recognition.
Antisense cFLIP-mediated elimination of either chronically
activated T cells (that is, autoimmunity) or naive T-cells
responding to alloantigens (that is transplantation), or
chemical modification of self-antigens (hapten-induced
contact sensitivity) could provide a potent and specific
therapeutic effect. Additionally, this treatment would be
long-lived because the immune system is unable to replenish
highly avid antigen-specific T-cell clones once the precursor
population has been removed from the T-cell repertoire. The
specific elimination of T cells producing inappropriate
responses, such as responses to self-antigens, transplanted
tissues, or allergens, would be a beneficial treatment option
for numerous human diseases.
MATERIALS AND METHODS
Mice
BALB/c, C57BL/6, and OT-1 mice aged 6–12 weeks obtained from
Simonsen or Charles River Laboratories (Shrewsbury, MA) were
housed in micro-isolator cages (3–5 mice per cage) during
acclimatization and treatment periods. Animals were exposed to a
12-hour light/dark cycle in a temperature- and humidity-controlled
environment and allowed access to sterilized rodent diet and water.
Temperature controls were set to maintain temperatures at 18–26 1C.
Autoclaved caging, water bottles, and storage containers were used
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to avoid exposure of animals to any contaminated materials.
Institutional approval for animal care and use protocols described
in these studies were granted according to the research guidelines at
Evanston Northwestern and Oregon State University.
Peptide-conjugated PMO
PMOs were synthesized at AVI BioPharma (Corvallis, OR) as
described earlier (Summerton and Weller, 1997). Purity was
495% as determined by reverse-phase HPLC and matrix-assisted
laser desorption/ionization time-of-flight mass spectrometer. PPMO
was produced by attaching the C-terminal cysteine of the peptide
(RRRRRRRRRFFC) to the 50-end of the PMO through a cross-linker
N-[a-maleimidobutyryloxy] succinimide ester (BGBS) (Moulton and
Moulton, 2003). PPMO was dissolved in sterile H2O before use in
cell cultures or diluted in phosphate-buffered saline (PBS) before
injection into mice.
cFLIP PMO sequence: 50-CTGGGCCATGTTCAGAACC-30.
Scrambled PMO sequence: 50-TGCGCGTCATGTACGCCAA-30.
Cell culture
Splenocyte suspensions in Dulbecco’s Modified Eagle’s/high glucose
and 1% fetal bovine serum media were made by passing macerated
spleens though nylon cell strainers and cultured (1.5 million/well in
96-well V-bottom plates) in mouse complete media (MCM¼RPMI
plus 10% fetal bovine serum (Hyclone, Logan, UT), 1% antibiotic-
antimycotic stock (Cellgro, Mediatech, Manassas, VA) (10,000 IU
penicillin, 10,000mgml1 streptomycin, and 25mgml1 ampho-
tericin), 2mM L-glutamine, and 50 mM b-mercaptoethanol). DCs used
in co-culture with OT-1 splenocytes were derived from bone marrow
cells extracted from the tibia and femurs of C57BL/6 mice cultured
for 8 days in mouse complete media containing recombinant murine
GM-CSF (25 ngml1) and IL-4 (5 ngml1). Mature DCs were used to
present SIINFEKL or irrelevant (RPQASGVYN) peptide (1mgml1) in
culture media overnight or in control (no antigen). DCs were
induced to undergo maturation by the addition of LPS (100 ngml1)
during overnight incubation followed by three washes in sterile PBS
before co-culturing with OT-1 splenocytes at a ratio of 2:1,
respectively.
Immunoblot analysis
Lysates of homogenized splenocytes in lysis buffer (1 PBS, 1%
Nonidet P-40, 0.5% sodium deoxycholate, and 0.2% SDS) with Mini
EDTA-free (Boehringer-Mannheim, Indianapolis, IN) protease in-
hibitor cocktail tablets added were centrifuged at 15,000 g for
20minutes at 4 1C, and the supernatant was removed and stored at
80 1C. Each sample was prepared by mixing 0.05mg of lysate
protein in 0.01ml of SDS and 5% 2-mercaptoethanol, and loaded
onto an ISC Bioexpress 10% (v/v) SDS/acrylamide gel. Protein was
transferred to Immobilon-P membranes (Millipore, Bedford, MA).
The membranes were allowed to dry, presoaked in methanol, and
incubated with blocking buffer (20mM Tris base, 150mM NaCl, 4%
nonfat milk, and 0.3% Tween 20) for 1 hour at room temperature.
The membranes were incubated for 2 hours with primary antibodies
diluted 1:1,000 in blocking buffer. Primary antibodies were used for
FLIPs/l (clone G-11; Santa Cruz Biotechnology, Santa Cruz, CA),
GAPDH (clone RGM2; Advanced ImmunoChemical Inc., Long
Beach, CA), and Actin (clone AC-40; Sigma, St Louis, MO).
Membranes were washed repeatedly with wash buffer (1 PBS
and 0.3% Tween 20) and incubated for 30minutes with an appro-
priate secondary antibody (1:2,000) conjugated with horseradish
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peroxidase. After washing, the membrane was incubated for
1minutes with an enhanced chemiluminescence Western Blot
Reagent (Amersham, Arlington Heights, IL) and then exposed to
Kodak Biomax film for 15–30 seconds and the film developed.
Flow cytometry
Immediately after treatment, the cultures were washed twice with
cold FACS buffer (PBSþ 1% fetal calf serumþ 0.02% (w/v) sodium
azide). All cultures were suspended in 100ml of Fc-blocking
antibody (eBioscience, San Diego, CA) (0.5mg/well) for 15minutes
on ice. Staining of lymphocyte populations was performed using
anti-CD4 or anti-KJ26 PE-Texas Red (0.3 mg/million cells; CalTag) or
anti-CD45R (clone B220) antigen-presenting cells (eBioscience)
(0.4 mg/million cells) for 30minutes on ice. Splenocytes from OT-1
mice were treated with cFLIP PPMO (1–12 mM), control PPMO, or
media alone overnight. The next day splenocytes were washed twice
with RPMI and then co-cultured with either SIINFEKL peptide-pulsed
(2mgml1) DCs or RPQASGVYN peptide-pulsed DCs for 24 hours.
Cells were harvested, Fc treated, and then stained with anti-CD8a
Alexa 488 (0.8 mg/million cells; BD Pharmingen, San Jose, CA).
Half of the cells were used in the Annexin-V/7-ADD staining
procedure as per the manufacturer’s directions (BD Pharmingen).
Cell staining was measured using a FACSCalibur flow cytometer
(Becton Dickinson, Franklin Lakes, NJ). Flow data were
analyzed using FCS Express 2 Pro software (Denovo software,
Los Angeles, CA). The observations were fit with a sigmoid curve
Y¼ bottomþ (top–bottom)/(1þ 10%ðlog EC50X ÞÞ using GraphPad
Prism software.
DO.11 splenocyte transplant
Splenocyte suspensions were extracted from DO.11 mice (18 males
and 2 females) on the day before the transplant, pooled separately
according to gender, and cultured at 37 1C overnight in complete
RPMI media. Recipient female BALB/c mice (N¼ 4 or 7 for two
separate experiments) received 300mg of the appropriate PMO by i.p.
injection of 100ml of PBS on days3,1, 0, 1, 2, 3, and 6, and 200ml
on days 7, 8, 9, and 10 relative to time of transplantation. On the day
of transplant, recipient mice were anesthetized with isofluorane, and
19 106 of DO.11 male splenocytes in 100ml PBS were delivered
into the retro-orbital sinus cavity of each mouse with a 25G 0.5-inch
needle. Two recipient BALB/c mice received 19 106 of female
DO.11 splenocytes by the same route. Fourteen days later, spleens
were collected from each recipient mouse and individually processed
for flow analysis to determine the number of KJ26þ cells in spleens of
each animal. Briefly, cells were washed, Fc blocked and stained with
anti-CD4 and anti-KJ26 FITC, and the red blood cells were lysed (as
described above). Stained splenocytes from a male DO.11 mouse
served as a gating control. Approximately one million events within
the live lymphocyte gate were examined for each sample to
enumerate the KJ26þ cells present. The total number of surviving
KJ26þ cells was computed by multiplying the percentage of cells
within the live gate by the total events collected by the total number or
splenocytes enumerated for the particular recipient examined. The
functionality of the transplanted cells was examined by inner cellular
cytokine staining using 500ml of each splenocyte suspension added to
duplicate wells each of a 24-well plate. OVA (200mgml1) in 100ml
was added to one well and 100ml media to the other for 24hours.
The final 4 hours GolgiPlug (BD Pharmingen) was added to each well.
Cells were stained with anti-KJ26, and cytokine production was
detected by permeabilization of the cell membranes with the CytoFix/
CytoPerm reagent (BD Pharmingen) and staining with anti-IL4
antigen-presenting cells (0.5mg/million cells) and anti-IFN-g FITC
(2mg/million cells) (both from BD Pharmingen). Cells were gated on
the KJ26þ region and the percentage of cytokine-positive KJ26þ
cells determined by flow analysis.
Hypersensitivity assay
On day 0, bellies of the mice (n¼ 6–9) were shaven using animal
clipper (Oster 40, McMinnville, TN). The animals were sensitized by
pipetting either 20 ml of 0.5% FITC diluted in acetone/dibutyl
phthalate (4:1) or 2% oxazolone (4-ethoxymethylene-2-phenyl-2-
oxazolin-5) diluted in acetone/olive oil (4:1), onto the shaved region.
On day 5, the animals were pretreated with 20 ml of cFLIP PPMO or
scrambled sequence PPMO (AVI BioPharma, Corvallis, OR)
dissolved in 95% propylene glycol and 5% linoleic acid. On day
6, mice were pretreated again with PMO. Approximately 15minutes
later, the eliciting dosage, either 10 ml of 0.2% FITC diluted in
acetone/dibutyl phthalate (4:1) or 1% oxazolone diluted in acetone/
olive oil (4:1), was applied to each side of one ear. Twenty four hours
later, ear thickness measurements were taken on both ears, using a
Starrett Caliper (#1015MH, Athol, MA). Each reading was performed
three times and the median value was used for all analysis.
The memory response was tested by giving a second eliciting dose.
On day 21, 15 days after the initial elicitation, animals were treated
with either 10ml of 0.2% FITC diluted in acetone/dibutyl phthalate (4:1)
or 1% oxazolone diluted in acetone/olive (4:1), which were
epicutaneously applied to each side of the opposite ear. On day 26,
5 days after the second eliciting dose, the thickness of each ear was
measured. The animals (n¼ 6–9) were killed and their ears were
removed and placed into 10% buffered formalin solution for 24hours
for paraffin embedding, sectioning, and hematoxylin and eosin staining.
The differences between the thickness of treated and untreated
ears for each mouse were determined. The mean and the standard
error were then calculated and analysis of variance followed by a
Newman–Keuls post-test was performed with significance set at
Po0.05 using GraphPad Prism (GraphPad, San Diego, CA).
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